查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405775

癲癇藥物市場規模、佔有率、趨勢分析報告：按產品、地區、細分市場預測，2023-2030

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 91 Pages | 商品交期: 2-10個工作天內

價格

癲癇藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球癲癇藥物市場規模將達到153.5億美元，2023年至2030年複合年成長率為5.1%。

增加政府對有效治療癲癇發作的新藥市場開拓的資助是癲癇藥物市場成長的重要動力。美國癲癇協會 (AES) 與美國神經病學學會、癲癇基金會和格拉斯基金會等其他組織合作，為研究和開發活動提供資金。透過各種方式向醫生提供護理意識培訓。的程序。

此外，癲癇基金會、美國癲癇協會、佛羅裡達州中部癲癇協會、CURE Epilepsy 和 Anita Kaufmann 基金會等組織所進行的各種提高認知計畫正在進一步加速診斷和治療速度。預計這將在預測期內推動市場成長。

癲癇藥物市場報告亮點

  • 第二代抗癲癇藥物預計將成為成長第二快的細分市場。此細分市場包括拉莫三嗪（Lamictal）、左乙拉西坦（Keppra）、布瓦西坦（Briviact）、吡崙帕奈（Fycompa）等。
  • 第三代抗癲癇藥細分市場佔最大銷售佔有率，2022年約39.3%。促進該領域成長的主要因素包括作用機制改進、副作用更少的高效藥物的推出，以及新管道藥物的等待名單。
  • 2022年，北美地區的銷售佔有率最高，約45%，佔據市場主導地位。該地區癲癇的高盛行率和大量受影響的人是癲癇藥物市場的主要推動要素。
  • 據估計，亞太地區在預測期內的複合年成長率將達到 6.3%，增幅最高。癲癇部門間全球行動計劃、全球抗癲癇宣傳活動以及新一代抗癲癇藥物的推出等政府舉措的存在預計將成為推動該地區市場成長的因素。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 普及和成長前景圖
  • 市場動態
    • 市場促進因素分析
    • 市場抑制因素分析
  • 普及和成長前景圖
  • 全球癲癇藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 癲癇藥物市場：產品評估與趨勢分析

  • 癲癇藥物市場：重點
  • 癲癇藥物市場：2022 年和 2030 年產品趨勢和市場佔有率分析
  • 第一代抗癲癇藥
  • 第二代抗癲癇藥
  • 第三代抗癲癇藥

第5章 癲癇藥物市場：按藥物分類的區域估計和趨勢分析

  • 區域展望
  • 按地區分類的癲癇藥物市場：市場要點
  • 北美洲
    • 2018-2030 年市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 泰國
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 科威特

第6章競爭形勢

  • 主要市場參與企業的最新趨勢和影響分析
  • 市場參與企業分類
    • 比利時 UCB SA
    • 賽諾菲
    • 輝瑞日本公司
    • 大塚美國製藥股份有限公司
    • Eisai
    • 諾華公司
    • 雅培實驗室公司
    • 賽諾菲亞萬蒂斯公司
    • GlaxoSmithKline Plc公司
    • 尚諾維製藥有限公司
    • 爵士製藥公司
    • 新瑞利斯有限公司
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Penetration & Growth Prospect Mapping
  • 3.5. Global Epilepsy Drug Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Epilepsy Drug Market: Key Takeaways
  • 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. First Generation Anti-epileptics
    • 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Second Generation Anti-epileptics
    • 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Third Generation Anti-epileptics
    • 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug

  • 5.1. Regional Outlook
  • 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. UCB S.A., Belgium
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Product Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Sanofi
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Product Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Pfizer, Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Product Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Otsuka America Pharmaceutical, Inc.
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Product Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Eisai Co., Ltd.
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Product Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Novartis AG
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Product Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Abbott Laboratories, Inc.
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Product Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Sanofi Aventis S.A.
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Product Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. GlaxoSmithKline plc
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Product Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Sunovion Pharmaceuticals, Inc.
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Product Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Jazz Pharmaceuticals plc
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Product Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Neurelis, Inc.
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Product Benchmarking
      • 6.2.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 4 U.S. epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 8 Germany epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 18 China epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 Japan epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Thailand epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Australia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26 Brazil epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 31 South Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait epilepsy drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Epilepsy drug market: Market outlook
  • Fig. 9 Epilepsy drug market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Epilepsy drug market driver impact
  • Fig. 15 Epilepsy drug market restraint impact
  • Fig. 16 Epilepsy drug market strategic initiatives analysis
  • Fig. 17 Epilepsy drug market: Product movement analysis
  • Fig. 18 Epilepsy drug market: Product outlook and key takeaways
  • Fig. 19 First generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Second generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Third generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global epilepsy drug market: Regional movement analysis
  • Fig. 23 Global epilepsy drug market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)